CA-SIGHTCALL
8.9.2021 10:02:12 CEST | Business Wire | Press release
SightCall, the world’s leading augmented reality (AR)-powered visual assistance platform, today announced its partnership with Italy’s Lavazza Group to offer AR-powered remote visual assistance for customer care and maintenance of its coffee machines. One of the world’s most important coffee roasters and a global enterprise with products and distributors in more than 140 countries, Lavazza Group is accelerating its use of virtual assistance technologies to support the ongoing expansion of its product portfolio and continued efforts to become more responsive to fast-changing consumer needs.
“We are proud to partner with Lavazza Group to provide global service solutions for easier and faster product maintenance and repair,” said Thomas Cottereau, founder and CEO of SightCall. “Now more than ever, the world’s top brands are turning to digital support that allows them to provide issue resolution with minimal service disruption. SightCall will enable Lavazza to work through customer care issues immediately, maintaining their hard-earned reputation for high-quality coffee products.”
SightCall provides the company with a comprehensive visual support tool for customer service agents to guide customers to troubleshoot issues, such as descaling coffee machines or basic accessory maintenance remotely. The AR interface lets remote agents draw, point and highlight onto the customer’s smartphone, and high-definition picture assures the highest call qualities even in low-bandwidth environments. Device-agnostic, SightCall performs on a range of user products from smartphones and tables to specialist equipment such as smart glasses.
Lavazza Group, with more than 4,000 employees and revenues of more than EUR 2 billion (2020 Financial Statement), switched to SightCall from a previous visual assistance provider. This decision stemmed from its desire to move from a local approach to a global template offering maximum portability and seamless CRM integration, reinforced by strong GDPR compliance.
Lavazza first piloted SightCall with its customer service teams in France and Germany in the middle of the COVID-19 lockdown in April. Customer support teams were impressed by the ease of use and the level of confidence quickly developed with the tool, providing them with good insight into how a long-term partnership would work.
The company has plans to scale up usage to 130+ customer support agents in seven countries over the next three years. The company plans to cover multiple regions of the world where it provides products, bolstered by the SightCall app’s ability to operate in 13 different languages. Lavazza will also increase the number of codes and use cases it applies SightCall to, with more readily available data from its CRM and responses to SightCall customer surveys telling it where visual assistance can best be deployed to resolve maintenance issues.
“Everywhere our coffee is consumed, Lavazza innovates to enhance the experiences of our customers and consumers, providing fast and accessible service when and where they need it,” said Maria Cristina Aspesi, Lavazza Group Customer Care Director. “With SightCall, we have chosen a solution that gives both central and local customer care teams a single, cutting-edge tool to help customers and consumers, increasing the number of support and interaction cases that can be solved instantaneously.”
About SightCall
SightCall is the world’s leading augmented-reality powered video cloud platform, delivering live, remote interactions between business and customers on every continent around the globe. In a connected, mobile-first world, businesses leveraging SightCall have the ability to see what their customers see and guide them remotely. With nearly 15 years of experience in remote video assistance, SightCall helps businesses transform their customer service and field service with the power of augmented reality and live video. The company has offices in San Francisco (HQ), Austin, Boston, Frankfurt, London, Melbourne, Paris and Singapore. Visit sightcall.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005412/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom